The side effects, such as neurotoxicity or CRS are the major issues in CAR T cell therapies, and other research groups have reported CRS after exposure to CAR T cells which have other targets in M7‐AMkL, such as folate receptor alpha (FOLR1).47 Here, FOLR1 is linked to congenital rubella syndrome.